GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

This is an accelerated approval based on response data and GSK ... doubts about whether Blenrep could be approved in the US after a FDA review noted problems with ocular safety associated with ...

A positive overall survival trend favoring the Blenrep combination was also observed at the time of this analysis. Furthermore, the safety and tolerability ... these data with regulators," the ...

That data should come from an ongoing phase 3 study comparing Blenrep with BMS’ immunomodulatory drug Pomalyst (pomalidomide) plus low-dose dexamethasone, the standard treatment option for ...

Data Sheet is a free, daily Fortune newsletter that decodes the day’s most pressing news about the business of technology. Each weekday, Fortune Brainstorm editorial director Andrew Nusca and ...

It is important to know how to read and interpret safety labels and SDSs (updated from Material Safety Data Sheets (MSDS) in 2016). SDSs use the Globally Harmonized System (GHS), a universal system ...

Process safety is about understanding hazards and risk, managing risk by providing the appropriate layers of protection to reduce the frequency and severity of incidents, and learning from incidents ...

Getty Images / Pekic A company's financial statements—balance sheet, income, and cash flow statements—are a key source of data for analyzing the investment value of its stock. Stock investors ...

And Blenrep is now filed with multiple regulators, including the U.S. I was also delighted to see the positive headline data from our mRNA ... offering strong safety, efficacy and overall ...